These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 330064)

  • 1. Migration inhibition factor and the blood clotting system: effects of defibrination, heparin and thrombin.
    Mäkinen T; Tötterman TH; Gordin A; Weber TH
    Clin Exp Immunol; 1977 Jul; 29(1):181-6. PubMed ID: 330064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
    Lämmle B; Griffin JH
    Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of antithrombin III assays using biological and chromogenic substrates.
    Philo RD; Gaffney PJ
    Br J Haematol; 1982 Jan; 50(1):147-56. PubMed ID: 7055531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of heparin on the activation of factor XI by fibrin-bound thrombin.
    von dem Borne PA; Meijers JC; Bouma BN
    Thromb Haemost; 1996 Sep; 76(3):347-53. PubMed ID: 8883269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin III: a backward glance o'er travel'd roads.
    Seegers WH
    Adv Exp Med Biol; 1975; 52():195-215. PubMed ID: 47704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effect of heparin in thrombin-antithrombin III interaction.
    Marciniak E
    Thromb Diath Haemorrh; 1975 Dec; 34(3):748-62. PubMed ID: 1209544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anticoagulating activity and lytic action of the heparin-antithrombin III and antithrombin III-heparin-thrombin complexes on non-stabilized fibrin].
    Kudriashov BA; Pastorova VE; Liapina LA
    Biokhimiia; 1981 Nov; 46(11):2024-9. PubMed ID: 7317530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of migration inhibitory factor activity by plasma esterase inhibitors.
    Remold HG; Rosenberg RD
    J Biol Chem; 1975 Aug; 250(16):6608-13. PubMed ID: 1099092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respective roles of antithrombin III and alpha 2 macroglobulin in thrombin inactivation.
    Fischer AM; Tapon-Bretaudiere J; Bros A; Josso F
    Thromb Haemost; 1981 Feb; 45(1):51-4. PubMed ID: 6166063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucocyte migration inhibition factor (LIF) and antithrombin III (AT III).
    Weber TH; Mäkinen T; Welin MG
    J Clin Lab Immunol; 1980 Jul; 4(1):47-8. PubMed ID: 7007650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of heparin on the early stages of blood coagulation.
    O'BRIEN JR
    J Clin Pathol; 1960 Mar; 13(2):93-8. PubMed ID: 14428016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulant effects of heparin in neonatal plasma.
    Schmidt B; Ofosu FA; Mitchell L; Brooker LA; Andrew M
    Pediatr Res; 1989 Apr; 25(4):405-8. PubMed ID: 2726317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring complex formation in the blood-coagulation cascade using aptamer-coated SAW sensors.
    Gronewold TM; Glass S; Quandt E; Famulok M
    Biosens Bioelectron; 2005 Apr; 20(10):2044-52. PubMed ID: 15741074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
    Berry CN; Girardot C; Lecoffre C; Lunven C
    Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin.
    Chan HH; Leslie BA; Stafford AR; Roberts RS; Al-Aswad NN; Fredenburgh JC; Weitz JI
    Biochemistry; 2012 Oct; 51(40):7964-73. PubMed ID: 22978548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postclotting fates of thrombin.
    Seegers WH
    Semin Thromb Hemost; 1986 Jul; 12(3):181-3. PubMed ID: 3775386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.